Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $3.16, $2.17 better than the analyst estimate of $0.99. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $474.26 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US government plans $4 billion loan to Vistra for nuclear upgrades - Bloomberg
- Mijem to consolidate shares 10-to-1, appoints new director
- NeuroSense faces Nasdaq delisting risk over market value rule
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
